Genetic Variants in Linear Localized Scleroderma


The purpose of this study is to investigate the genetic architecture of Linear Localized Scleroderma (LLS) (linear morphea) by whole exome sequencing.

Full Title of Study: “Investigation of the Genetic Architecture of Linear Localized Scleroderma (LLS) (Linear Morphea) by Whole Exome Sequencing. A Tailored Approach to Test the Hypothesis That LLS is a Genetic Mosaic Condition”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2017

Detailed Description

At present the etiology of LLS is unknown, but a genetic background is suspected. Although LLS clearly classifies as a mosaic disorder, its genetics and protein machinery remain to be understood. We are going to use a tailored approach to identify the genetic factors of LLS. In the first phase of the study we will investigate the genetic architecture in LLS. WES will analyze whole protein coding DNA in skin samples of 50 consenting LLS patient. The aim is to identify the key genes associated with LLS. In the second phase of the study subsequent functional experiments will be performed. Based on the identified candidate genes, knockdown and overexpression models will be created with relevant cell lines (fibroblasts) to identify the biological consequences and confirm the functional relevance of the identified genetic mutations in LLS. Further the protein network active in LLS will be investigated (proteomic analysis). The described basic genetic studies combined with functional experiments will lay the groundwork for treatment trials to provide possibly novel treatment options.


  • Other: skin biopsy

Arms, Groups and Cohorts

  • Other: skin biopsy
    • 4mm punch biopsy

Clinical Trial Outcome Measures

Primary Measures

  • number of key genes /number of mutations in LLS (localized linear scleroderma)
    • Time Frame: 24-30 months

Secondary Measures

  • the investigation of the protein network of the identified key genes in order to assess their biological function and their relevance in the pathogenesis of LLS.
    • Time Frame: 24-30 months

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female subjects ≥ 5 years of age with well phenotyped LLS – Affecting their head and / or face "termed " en coup de sabre " type LLS or Hemiatrophia faciei or Parry-Romberg syndrome, with or without therapy – Affecting any site of the body except the head or face, with or without therapy Exclusion Criteria:

  • Patients with signs of systemic scleroderma – Patients with localized scleroderma (morphea) other than the linear type ("plaque-type", "morphea profunda", "generalized morphea") Patients with diagnosed gadolinium induced scleroderma Patients with post-irradiation scleroderma Patients with missing consent

Gender Eligibility: All

Minimum Age: 5 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Children’s Hospital, Zurich
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Lisa Weibel, MD, Principal Investigator, Department Pediatric Dermatology University Children’s Hospital Zurich

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.